DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET ANALYSIS
Global Duchenne Muscular Dystrophy Treatment Market: Key Developments
In April 2022, Pfizer Inc. planned to open the first U.S. sites in the Phase III study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy.
In February 2021, Sarepta Therapeutics, Inc. announced that the U.S. Food & Drug Administration (FDA) has approved AMONDYS 45 (casimersen). AMONDYS 45 is an antisense oligonucleotide from the Sarepta’s phosphorodiamidate morpholino oligomer (PMO) platform, for the treatment of DMD in patients with a confirmed mutation amenable to exon 45 skipping.
In February 2021, the District Attorney (DA) of the United States approved Sarepta Therapeutics' Amondys 45 (casimersen injectable), an antisense oligonucleotide for the treatment of people with Duchenne Muscular Dystrophy.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
